These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24776521)

  • 1. Ivabradine: heart rate and left ventricular function.
    Ferrari R
    Cardiology; 2014; 128(2):226-30. PubMed ID: 24776521
    [No Abstract]   [Full Text] [Related]  

  • 2. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction.
    Manz M; Reuter M; Lauck G; Omran H; Jung W
    Cardiology; 2003; 100(3):149-55. PubMed ID: 14631136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correction of sinus rate by inhibitors of If-channels in patients with acute decompensated heart failure].
    Saĭganov SA; Karchik'ian PO
    Kardiologiia; 2014; 54(11):34-8. PubMed ID: 25902657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
    Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
    Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine.
    Bohora S; Lokhandwala Y; Parekh P; Vasavda A
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):340-2. PubMed ID: 20653812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction.
    Sette A; Martino A; Lioy E; Calò L
    J Cardiovasc Electrophysiol; 2010 Jul; 21(7):815-7. PubMed ID: 20233274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia.
    Fang Y; Debunne M; Vercauteren M; Brakenhielm E; Richard V; Lallemand F; Henry JP; Mulder P; Thuillez C
    J Cardiovasc Pharmacol; 2012 Mar; 59(3):260-7. PubMed ID: 22075752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC; Reil GH; Böhm M
    Trends Cardiovasc Med; 2009 Jul; 19(5):152-7. PubMed ID: 20005474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy.
    Parsons S; Clark AL; Cleland JG
    Clin Res Cardiol; 2014 Oct; 103(10):847-9. PubMed ID: 24920068
    [No Abstract]   [Full Text] [Related]  

  • 10. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure.
    De Ferrari GM; Mazzuero A; Agnesina L; Bertoletti A; Lettino M; Campana C; Schwartz PJ; Tavazzi L
    Eur J Heart Fail; 2008 Jun; 10(6):550-5. PubMed ID: 18486549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure.
    Ozturk S; Öztürk S; Erdem FH; Erdem A; Ayhan S; Dönmez İ; Yazıcı M
    J Interv Card Electrophysiol; 2016 Sep; 46(3):253-8. PubMed ID: 27039084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of ivabradine and atenolol in patients with moderate mitral stenosis in sinus rhythm.
    Rajesh GN; Sajeer K; Sajeev CG; Bastian C; Vinayakumar D; Muneer K; Haridasan V; Mathew D; George B; Krishnan MN
    Indian Heart J; 2016; 68(3):311-5. PubMed ID: 27316483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N
    Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical-hemodynamic and anti-ischemic effects ivabradine and nebivolol ischemic heart disease with left ventricular dysfunction].
    Abuladze GV; Kvirkveliia AA; Nebieridze MI; Chachua TB; Dundua GI
    Georgian Med News; 2010 Oct; (187):24-7. PubMed ID: 21098889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
    Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study.
    Hidalgo FJ; Anguita M; Castillo JC; Rodríguez S; Pardo L; Durán E; Sánchez JJ; Ferreiro C; Pan M; Mesa D; Delgado M; Ruiz M
    Int J Cardiol; 2016 Aug; 217():7-11. PubMed ID: 27167103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correction of cardiodynamic disorders in experimental diabetes by omega-3 polyunsaturated fatty acids].
    Zhukovs'ka AS; Shysh AM; Kuz'menko MO
    Fiziol Zh (1994); 2013; 59(2):100-3. PubMed ID: 23828977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.